Why have they used an 8 year old publication (looking at antiquated gemcitabine alone v gemcitabine + radiotherapy in a small population) to support their claim that current OS is 9-11 months?
In this Nov, 2018 article looking at FOLFIRINOX v radiotherapy in a population of LAPC, OS was found to be 15.4 months. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221154/
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
0.210(20.6%) |
Mkt cap ! $17.49M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.24 | $1.03 | $200.2K | 169.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 60000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |